$MACK (Merrimack Pharmaceuticals, Inc.)

$MACK {{ '2016-10-03T16:20:06+0000' | timeago}} • Announcement

$MACK said it reduced 22% of its headcount while eliminating more than $200MM in expected costs over the next 2 years. The company also said its CEO Robert Mulroy resigned, effective immediately. The BoD appointed Chairman Gary Crocker as interim CEO. $MACK had reported a 2Q16 loss of $50.8MM, hurt by higher R&D costs and interest expenses.

$GILD {{ '2017-07-27T19:17:21+0000' | timeago}} • Webcast

$GILD stated that for Genvoya, it is starting to see performance trends similar to that of the US in other countries like Germany. The company is seeing good uptake in Spain and Italy. France has also done extraordinarily well in just four months to become the leading naïve and switch product.

$CELG {{ '2017-07-27T19:16:33+0000' | timeago}} • Announcement

For FY17, $CELG cut down its GAAP EPS outlook to $5.36-5.62 from its prior estimate of $5.95-6.29. However, Celgene lifted its non-GAAP EPS outlook to $7.25-7.35 from its previous estimate of $7.15-7.30. The company didn't alter its previous revenue outlook of $13.0-13.4Bil.

$GILD {{ '2017-07-27T19:04:57+0000' | timeago}} • Webcast

For HCV, $GILD’s total revenues in the US were $1.9Bil in 2Q17, down 17% YoY and up 13% sequentially. The QoQ increase was primarily due to a change in inventory and the timing of patient starts. In Europe, total HCV revenue was $591MM, down 24% YoY and up 21% from 1Q17.

$GILD {{ '2017-07-27T19:00:11+0000' | timeago}} • Webcast

$GILD is seeing strong uptake of its TAF-based regimens in the US and Europe. In the US, total HIV and HBV revenues were $2.6Bil for 2Q17, up 19% YoY and up 10% sequentially. In Europe, total HIV and HBV revenues were $732MM, down 3% YoY and up 5% sequentially. The YoY decrease was driven by negative foreign exchange.

$CELG {{ '2017-07-27T18:53:16+0000' | timeago}} • Announcement

Biotech heavyweight $CELG reported strong profit in 2Q17, helped by higher product sales. Net income of $1.06Bil and diluted EPS of $1.31, surged 77% and 75%, respectively. Total revenue rose 19% to $3.3Bil, while  net product sales alos increased 19% for the recent quarter. Celgene's earnings grew 26% to $1.82 per share on an adjusted basis.

$GILD {{ '2017-07-27T18:32:52+0000' | timeago}} • Announcement

$GILD declared a cash dividend of $0.52 per share of common stock for 3Q17, payable on September 28, 2017, to stockholders of record on September 15, 2017.

$CELG {{ '2017-07-27T14:01:16+0000' | timeago}} • Infographic

$CELG Celgene Earnings AlphaGraphic: Q2 2017 highlights

$BMY {{ '2017-07-27T12:44:31+0000' | timeago}} • Infographic

$BMY Bristol-Myers Squibb Co Earnings AlphaGraphics: Q2 2017 highlights

$BMY {{ '2017-07-27T11:32:39+0000' | timeago}} • Announcement

$BMY updated its FY17 GAAP EPS guidance range to $2.66-2.76 and raised the lower end of its non-GAAP EPS guidance range to $2.90-3.00, as the pharma giant posted 2Q17 results.

$ALXN {{ '2017-07-27T11:31:03+0000' | timeago}} • Announcement

$ALXN's sale of its flagship drug Soliris was $814MM in 2Q17, compared to $701MM in the prior-year period, representing a 16% increase. Soliris volume increased 18% YoY. Soliris is primarily used to treat a rare disorder that destroys red blood cells.

$BMY {{ '2017-07-27T11:30:29+0000' | timeago}} • Announcement

As $BMY posted its 2Q17 results, it also announced that the European Commission (EC) approved its drug ORENCIA alone or in combination with methotrexate for the treatment of active Psoriatic Arthritis in certain adult patients.

$BMY {{ '2017-07-27T11:28:03+0000' | timeago}} • Announcement

A 31% surge in R&D expenses of $1.7Bil in 2Q17 saw $BMY's net attributable earnings slumping 24% to $916MM, even as revenue rose 6% to $5.1Bil. Diluted EPS slipped 19% to $0.56, while non-GAAP diluted EPS rose 7% to $0.74.

$ALXN {{ '2017-07-27T11:20:47+0000' | timeago}} • Announcement

$ALXN raised its 2017 forecast for both GAAP and non-GAAP revenue to $3.45-3.525Bil, vs the prior guidance of $3.40-3.50Bil. Non-GAAP EPS projection for this period was also raised to $5.40-5.55, compared to the prior guidance of $5.10-5.30. Meanwhile, the company now sees GAAP EPS in the range of $2.82-3.12.

$ALXN {{ '2017-07-27T11:10:27+0000' | timeago}} • Announcement

Global biopharmaceutical company $ALXN reported 21% jump in revenue in 2Q17 to $912MM. The revenue reflected a benefit of about $35MM due to favorable timing of orders compared to its prior forecast. Net income rose to $165MM, or $0.73 per share, from $120MM, or $0.53 per share, a year ago. On an adjusted basis, $ALXN earned $1.56, up 38% YoY.

$GILD {{ '2017-07-26T21:10:46+0000' | timeago}} • Infographic

$GILD Gilead Sciences Earnings AlphaGraphic: Q2 2017 Highlights

$VRTX {{ '2017-07-26T20:38:11+0000' | timeago}} • Announcement

$VRTX also reviewed its recent progress toward treating all people with cystic fibrosis, including the completion of an asset purchase agreement with Concert Pharmaceuticals for worldwide development and commercialization rights to CTP-656 and other assets related to the treatment of cystic fibrosis.

$GILD {{ '2017-07-26T20:37:51+0000' | timeago}} • Announcement

$GILD revised its FY17 guidance. The company now expects net product sales to be $24-25.5Bil in FY17. Non-HCV product sales are expected to be $15.5-16Bil while HCV product sales are expected to be $8.5-9.5Bil. Adjusted product gross margin is expected to be 86-88% in FY17.

$VRTX {{ '2017-07-26T20:36:21+0000' | timeago}} • Announcement

$VRTX lifted 2017 non-GAAP combined research & development and selling, general & administrative expenses outlook to $1.33-1.36Bil from $1.25-1.30Bil, and GAAP combined R&D and SG&A expenses estimate to $1.79-1.92 from $1.55-1.70. The updated forecast reflects the progression of the company's cystic fibrosis portfolio.

$GILD {{ '2017-07-26T20:33:53+0000' | timeago}} • Announcement

$GILD's total product sales for 2Q17 were $7Bil compared to $7.7Bil for 2Q16. Product sales were $5Bil in the US, $1.4Bil in Europe and $665MM in other locations during 2Q17. Antiviral product sales were $6.4Bil and Other product sales were $607MM for 2Q17.

$VRTX {{ '2017-07-26T20:33:48+0000' | timeago}} • Announcement

$VRTX expects 2017 total cystic fibrosis product revenue of $1.84-2.07Bil, comprised of Orkambi and Kalydeco product revenues. $VRTX still expects 2017 product revenue for Orkambi of $1.1-1.3Bil and for Kalydeco of $740-770MM.

Recent Transcripts

VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, July 26 2017 - 9:15pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
LLY (Eli Lilly and Company)
Tuesday, July 25 2017 - 1:00pm
MMM (3M Company)
Tuesday, July 25 2017 - 1:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
SCLN (SciClone Pharmaceuticals, Inc.)
Wednesday, May 10 2017 - 8:30pm
MACK (Merrimack Pharmaceuticals, Inc.)
Wednesday, May 10 2017 - 12:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
INFI (Infinity Pharmaceuticals, Inc.)
Tuesday, May 9 2017 - 8:30pm
OPK (Opko Health, Inc.)
Tuesday, May 9 2017 - 8:30pm
BMRN (BioMarin Pharmaceutical Inc.)
Thursday, May 4 2017 - 8:30pm
INCY (Incyte Corporation)
Thursday, May 4 2017 - 2:00pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
SPPI (Spectrum Pharmaceuticals, Inc.)
Tuesday, May 2 2017 - 8:30pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm

AlphaGraphics you may like